Choreo LLC Sells 8,622 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Choreo LLC reduced its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 17.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 40,693 shares of the company’s stock after selling 8,622 shares during the quarter. Choreo LLC’s holdings in Elanco Animal Health were worth $481,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. ORG Wealth Partners LLC bought a new stake in shares of Elanco Animal Health during the third quarter valued at approximately $29,000. AM Squared Ltd acquired a new stake in Elanco Animal Health in the 3rd quarter valued at $34,000. Wilmington Savings Fund Society FSB bought a new stake in Elanco Animal Health during the 3rd quarter valued at $35,000. Farther Finance Advisors LLC increased its stake in Elanco Animal Health by 158.7% during the 3rd quarter. Farther Finance Advisors LLC now owns 3,332 shares of the company’s stock valued at $49,000 after purchasing an additional 2,044 shares in the last quarter. Finally, Venturi Wealth Management LLC lifted its stake in shares of Elanco Animal Health by 89.9% in the third quarter. Venturi Wealth Management LLC now owns 3,382 shares of the company’s stock valued at $50,000 after buying an additional 1,601 shares in the last quarter. Institutional investors own 97.48% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on ELAN. Leerink Partners started coverage on shares of Elanco Animal Health in a research report on Monday, December 2nd. They set a “market perform” rating and a $14.00 target price for the company. Stifel Nicolaus decreased their price objective on Elanco Animal Health from $20.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Leerink Partnrs upgraded Elanco Animal Health to a “hold” rating in a report on Monday, December 2nd. UBS Group assumed coverage on Elanco Animal Health in a report on Monday, December 9th. They set a “buy” rating and a $18.00 price target for the company. Finally, Barclays raised their price objective on Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, November 8th. One analyst has rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, Elanco Animal Health presently has an average rating of “Hold” and a consensus price target of $16.29.

Elanco Animal Health Stock Performance

Shares of ELAN opened at $11.42 on Wednesday. The stock has a 50 day moving average of $11.99 and a 200 day moving average of $13.18. The company has a market capitalization of $5.65 billion, a price-to-earnings ratio of 28.55, a PEG ratio of 2.69 and a beta of 1.42. Elanco Animal Health Incorporated has a 12 month low of $11.11 and a 12 month high of $18.80. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.